In vitro method for determining cholestatic properties of a compound by Peijnenburg, A.A.C.M. & Szalowska, E.
Printed by Jouve, 75001 PARIS (FR)
(19)
E
P
2 
76
2 
57
3
A
1
TEPZZ 76 57¥A_T
(11) EP 2 762 573 A1
(12) EUROPEAN PATENT APPLICATION
(43) Date of publication: 
06.08.2014 Bulletin 2014/32
(21) Application number: 13154103.9
(22) Date of filing: 05.02.2013
(51) Int Cl.:
C12Q 1/68 (2006.01)
(84) Designated Contracting States: 
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 
PL PT RO RS SE SI SK SM TR
Designated Extension States: 
BA ME
(71) Applicant: Rikilt
6708 WB  Wageningen (NL)
(72) Inventors:  
• Peijnenburg, Adrianus Antonius Cornelis Maria
6701 CL WAGENINGEN (NL)
• Szalowska, Ewa
6843 RP ARNHEM (NL)
(74) Representative: Habets, Winand
Life Science Patents 
PO Box 5096
6130 PB  Sittard (NL)
(54) In vitro method for determining cholestatic properties of a compound.
(57) The invention is in the field of medical diagnos-
tics and molecular biology. It provides markers that may
be used in an in vitro method for determining whether a
compound has cholestatic properties. More in particular,
the invention relates to an in vitro method for determining
whether a compound has cholestatic properties, com-
prising the step of exposing a liver cell to the compound,
incubating the liver cell with the compound for an appro-
priate amount of time, determining the expression level
of genes Bcl2l11, Parp 16, Mras, Myo1e, Nme6 ABCG5,
ABCG8, SERPINE1, BAAT, and KLF15 in the liver cell,
wherein an aberrant expression of more than 4 of these
genes indicates that the compound has cholestatic prop-
erties.
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Description
Field of the invention
[0001] The invention is in the field of medical diagnostics and molecular biology. It provides markers that may be used
in an in vitro method for determining whether a compound has cholestatic properties.
Background of the invention
[0002] Drug induced liver injury is still a major problem in medical care and pharmacological industry. One example
of severe liver damage is cholestasis (Padda et al. 2011) that comprises approximately 17% of all hepatic adverse drug
reactions (Velayudham and Farrell 2003). Cholestasis results in a dramatic increase in liver and serum bile acids that
eventually can lead to liver failure (Woolbright and Jaeschke 2012). Several currently used drugs have been shown to
induce cholestasis in humans and rats, e.g. cyclosporine A (CsA) used as an immunosuppressant (Chan et al. 1998;
Dandel et al. 2010; Deters et al. 1997; Rotolo et al. 1986), chlorpromazine (CPZ) applied as an antipsychotic (Abernathy
et al. 1992; Akerboom et al. 1991) and ethinyl estradiol (EE) (Lindberg 1992; Paulen et al. 2010; Zhao et al. 2009) used
as a compound of contraceptive pills. Bile acids (BA) are amphipathic molecules synthesized from cholesterol in hepa-
tocytes, which together with phospholipids and cholesterol are actively secreted by the liver as bile.
[0003] Upon a meal ingestion bile is released into the intestinal lumen to enable absorption of dietary lipids and fat-
soluble vitamins (Lefebvre et al. 2009). BA levels are tightly regulated because high BAs concentrations may become
cytotoxic (Lefebvre et al. 2009).
[0004] There is a lack of in vitro models that accurately predict development of drug induced cholestasis in humans.
Cell line models e.g.HepG2 or mouse primary hepatocytes are commonly used to detect drugs with cholestatic properties.
[0005] The spectrum of drug-induced cholestasis ranges from ’bland’ reversible cholestasis to chronic forms due to
the vanishing bile duct syndrome. Agents known for many years to cause cholestasis include estrogens and anabolic
steroids, chlorpromazine, erythromycin, and the oxypenicillins; structurally similar congeners of these drugs (tamoxifen,
newer macrolides) may also cause cholestasis. Contemporary drugs linked to cholestastic liver injury include ticlopidine,
terfenadine, terbinafine, nimesulide, irbesartan, fluoroquinolones, cholesterol-lowering ’statins,’ and some herbal rem-
edies (greater celandine, glycyrrhizin, chaparral). Amoxillin-clavulanate, ibuprofen, and pediatric cases of the vanishing
bile duct syndrome are recent additions to a long list of drugs associated with the vanishing bile duct syndrome. Particular
human leukocyte antigen profiles have recently been identified among those who have developed cholestasis with
specific drugs (tiopronin and amoxicillin-clavulanate)
[0006] In the development of new drugs, it is imperative that unwanted side-effects are recognized as early as possible.
Hence, there is an urgent need for a reliable test method that identifies compounds with cholestatic properties in an
easy, fast and economic way.
Summary of the invention
[0007] It was found that a liver cell responded with an altered level of certain genes when it was exposed to a compound
with cholestatic properties.
[0008] The invention therefore provides an in vitro method for determining whether a compound has cholestatic prop-
erties, comprising the step of exposing a liver cell to the compound, incubating the liver cell with the compound for an
appropriate amount of time, determining the expression level of genes Bcl2l11, Parp 16, Mras, Myo1e, Nme6 ABCG5,
ABCG8, SERPINE1, BAAT, and KLF15 in the liver cell, wherein an aberrant expression of more than 4 of these genes
indicates that the compound has cholestatic properties.
Detailed description of the invention
[0009] Liver cells were exposed to a variety of compounds as described in the examples section. As pro-cholestatic
model compounds CyclosporinA (CsA) and chlorpromazine (CPZ) were selected. Tetracycline (TETRA), valproic acid
(VA), and amiodarone (AMIOD) were used as model steatotic drugs. As a model for necrotic drugs acetaminophen
(APAP), paraquat (PQ) and isoniazid (ISONZ) were used at a maximum, non-cytotoxic dose. Both steatotic and necrotic
compounds could be regarded as negative controls i.e. non-cholestatic compounds Five mice were used in 5 separate
experiments as described in the Examples section.
[0010] Quantitative PCR test were developed as described in the Examples section. Relative expression levels (relative
to actin B expression levels) were determined for 10 genes as listed in table 1.
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[0011] The relative gene expression levels are presented as fold change in tables 2 - 9.
Table 1; Marker genes for cholestasis
Gene Function
BAAT The protein encoded by this gene catalyzes the transfer of the bile acid moiety from the acyl-CoA 
thioester to either glycine or taurine, the second step in the formation of bile acid-amino acid conjugates 
which serve as detergents in the gastrointestinal tract.
ABCG8 The protein encoded by this gene functions as a half-transporter to limit intestinal absorption and 
promote biliary excretion of sterols.
ABCG5 The protein encoded by this gene functions as a half-transporter to limit intestinal absorption and 
promote biliary excretion of sterols.
KLF15 KLF15 is increased by fasting and decreased by feeding. Plays a role in regulation of energy metabolism 
and gluconeogenesis.
SERPINE1 SERPINE1=PAI-1 is a serine protease inhibitor that functions as the principal inhibitor of tissue 
plasminogen activator (tPA) and urokinase (uPA), the activators of plasminogen, contributes to 
cholestatic injury in mice.
Nme6 NME6 is ubiquitous enzyme that catalyze transfer of gamma-phosphates, via a phosphohistidine 
intermediate, between nucleoside and dioxynucleoside tri- and diphosphates
Parp16 Poly (ADP-ribose) polymerase (PARP) catalyzes the post-translational modification of proteins by the 
addition of multiple ADP-ribose moieties. PARP transfers ADP-ribose from nicotinamide dinucleotide 
(NAD) to glu/asp residues on the substrate protein, and also polymerizes ADP-ribose to form 
long/branched chain polymers. PARP inhibitors are being developed for use in a number of pathologies 
including cancer, diabetes, stroke and cardiovascular disease.
Myo1e This gene encodes a member of the nonmuscle class I myosins which are a subgroup of the 
unconventional myosin protein family. The unconventional myosin proteins function as actin-based 
molecular motors. Class I myosins are characterized by a head (motor) domain, a regulatory domain 
and a either a short or long tail
domain. Among the class I myosins, this protein is distinguished by a long tail domain that is involved 
in crosslinking actin filaments. This protein localizes to the cytoplasm and may be involved in 
intracellular movement and membrane trafficking.
Mras This gene encodes a member of the Ras family of small GTPases. These membrane-associated 
proteins function as signal transducers in multiple processes including cell growth and differentiation, 
and dysregulation of Ras signaling has been associated with many types of cancer. The encoded 
protein may play a role in the tumor necrosis factor-alpha and MAP kinase signaling pathways.
Bcl2l11 The protein encoded by this gene contains a Bcl-2 homology domain 3 (BH3). It has been shown to 
interact with other members of the BCL-2 protein family, including BCL2, BCL2L1/BCL-X(L), and 
MCL1, and to act as an apoptotic activator.
Table 2: Gene expression levels for CsA as determined by qPCR in 5 mice.
Compound CsA CsA CsA CsA CsA MW CsA test
Gene *fold change 1 *fold change 2 *fold change 3 *fold change 4 *fold change 5
Bcl2111 -1,4 -1,0 1,2 -1,1 -1,1 NS
Parp 16 1,6 1,6 1,7 1,6 2,6 *
Mras 2,0 1,7 1,8 1,6 2,3 *
Myo 1e -1,5 -1,1 -1,3 -1,6 -1,7 *
Nme6 5,4 5,5 4,0 4,4 3,7 *
ABCG5 -3,5 -1,8 1,0 -1,3 1,2 NS
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(continued)
Compound CsA CsA CsA CsA CsA MW CsA test
Gene *fold change 1 *fold change 2 *fold change 3 *fold change 4 *fold change 5
ABCG8 -4,9 -3,9 -1,2 -2,0 -1,2 *
SERPINE1 -4,2 -3,2 1,1 -1,1 2,6 NS
BAAT -5,2 -4,2 -1,6 -2,2 -1,7 *
KLF15 -1,2 -1,7 -2,0 -1,4 -1,3 *
Table 3: Gene expression levels for CPZ as determined by qPCR in 5 mice.
Compound CPZ CPZ CPZ CPZ CPZ MW CPZ test
Gene *fold change 1 *fold change 2 *fold change 3 *fold change 4 *fold change 5
Bcl2111 -1,2 -1,4 -1,2 -1,9 -2,3 *
Parp 16 -1,1 -1,4 -1,1 -1,4 -1,0 *
Mras 1,3 2,0 2,6 1,4 1,1 *
Myo 1e -1,1 -1,0 1,1 1,0 -1,1 NS
Nme6 1,1 1,3 1,7 1,3 1,2 *
ABCG5 -4,2 -2,9 -6,7 -3,8 -1,0 *
ABCG8 -2,9 -2,1 -5,4 -4,5 -1,1 *
SERPINE1 2,9 -1,4 -4,7 -5,8 -1,8 NS
BAAT -2,3 -3,3 -8,5 -6,4 1,4 *
KLF15 -2,0 -1,8 -3,2 -1,8 1,6 NS
Table 4: Gene expression levels for APAP as determined by qPCR in 5 mice.
APAP APAP APAP APAP APAP MW APAP test
Gene *fold change 1 *fold change 2 *fold change 3 *fold change 4 *fold change 5
Bcl2111 1,9 1,1 2,0 2,4 1,7 *
Parp 16 1,4 -1,3 1,4 1,5 1,6 NS
Mras 1,7 -1,0 1,3 1,2 1,4 *
Myo 1e 1,1 -1,2 1,4 1,4 1,4 NS
Nme6 -1,2 -1,2 -1,1 -1,3 1,0 NS
ABCG5 -2,1 -1,3 1,4 -1,4 1,1 NS
ABCG8 -1,7 -1,2 1,4 -1,1 1,4 NS
SERPINE1 -1,6 -1,4 1,2 -1,3 1,5 NS
BAAT -5,0 -2,0 -1,4 -2,8 -1,5 *
KLF15 -1,5 -1,2 -1,4 -1,1 1,2 NS
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Table 5: Gene expression levels for PQ as determined by qPCR in 5 mice.
Compoun d PQ PQ PQ PQ PQ MW PQ test
Gene *fold change 1 *fold change 2 *fold change 3 *fold change 4 *fold change 5
Bcl2111 1,3 1,1 1,1 1,2 1,1 NS
Parp 16 1,6 1,0 1,0 1,1 1,4 NS
Mras 1,4 1,3 1,1 1,1 1,4 NS
Myo 1e 1,1 1,4 1,1 1,2 1,2 NS
Nme6 1,1 -1,2 1,0 1,1 1,2 NS
ABCG5 1,1 1,1 1,7 -1,3 -1,6 NS
ABCG8 1,0 -1,2 1,8 -1,3 -1,4 NS
SERPINE 1 2,7 2,3 2,7 1,3 1,9 *
BAAT -1,2 -1,0 1,7 1,1 -1,4 NS
KLF15 1,3 -1,0 1,3 1,1 -1,2 NS
Table 6: Gene expression levels for ISONZ as determined by qPCR in 5 mice.
Compoun d ISONZ ISONZ ISONZ ISONZ ISONZ MW ISONZ test
Gene *fold change 1 *fold change 2 *fold change 3 *fold change 4 *fold change 5
Bcl2111 1,9 1,7 1,3 -1,2 -1,2 NS
Parp 16 -1,0 -1,0 1,2 -2,3 -1,8 NS
Mras 1,7 -1,1 1,3 -1,3 -1,3 NS
Myo 1e 1,5 1,3 1,3 -1,3 1,1 NS
Nme6 1,3 1,2 1,1 -1,3 -1,1 NS
ABCG5 2,0 3,0 1,1 2,0 2,0 *
ABCG8 2,1 2,8 1,0 2,3 1,9 NS
SERPINE 1 5,4 1,9 1,4 -1,4 -2,9 NS
BAAT 1,8 1,7 1,1 -1,3 1,3 NS
KLF15 1,2 2,4 1,0 1,1 1,2 NS
Table 7: Gene expression levels for TETRA as determined by qPCR in 5 mice.
Compoun d TETRA TETRA TETRA TETRA TETRA MW TETRA test
Gene *fold change 1 *fold change 2 *fold change 3 *fold change 4 *fold change 5
Bcl2111 -1,1 1,6 1,5 1,5 1,1 NS
Parp 16 1,0 1,1 1,1 1,0 -1,1 NS
Mras 1,3 1,3 1,3 1,3 1,0 *
Myo 1e 1,0 1,2 -1,1 1,1 1,1 NS
Nme6 1,2 -1,4 -1,4 1,1 1,0 NS
ABCG5 -1,9 -3,1 -1,9 -5,4 -2,1 *
ABCG8 -1,5 -4,1 -1,8 -4,8 -2,0 *
SERPINE 1 -1,6 2,4 1,1 -3,2 -3,0 NS
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[0012] It is immediately apperant from the data presented above that the cholestatic compounds significantly alter the
gene expression of 7 out of 10 marker genes. Under the influence of CsA, genes Parp 16, Mras and Nme are upregulated
(i.e. a fold change of > 1) whereas genes Nyo 1 e, ABCG8, BAAT and KLF15 are downregulated (i.e. a fold change of
< -1). Remarkably, CPZ induced the upregulation of Mras, Nme and BAAT and the downregulation of Bcl2111, Parp
16, ABCG5 and ABCG8. The control compounds significantly altered the expression of at most 4 of these genes (tables
4 - 9).
[0013] It is therefore concluded that the aberrant expression of the 10 marker genes as identified herein are a useful
(continued)
Compoun d TETRA TETRA TETRA TETRA TETRA MW TETRA test
Gene *fold change 1 *fold change 2 *fold change 3 *fold change 4 *fold change 5
BAAT -2,2 -6,1 -2,7 -5,5 -3,1 *
KLF15 1,1 -1,9 -1,6 -2,4 -1,3 NS
Table 8: Gene expression levels for VA as determined by qPCR in 5 mice.
Compound VA VA VA VA VA MW VA test
Gene *fold change 1 *fold change 2 *fold change 3 *fold change 4 *fold change 5
Bcl2111 -1,0 -1,2 -1,2 -1,4 -1,3 *
Parp 16 -1,1 -1,5 -1,8 -1,4 -1,4 *
Mras 1,0 -1,2 -1,4 -1,3 1,2 NS
Myo 1e -1,1 -1,3 -1,5 -1,1 -1,3 *
Nme6 1,0 1,2 -1,5 1,4 1,7 NS
ABCG5 2,0 -1,7 -1,1 1,4 1,6 NS
ABCG8 2,2 -1,5 -1,3 1,4 1,9 NS
SERPINE1 1,5 -4,0 -1,3 -1,3 1,5 NS
BAAT 1,3 1,0 -2,0 1,4 2,5 NS
KLF15 1,0 -1,9 -1,7 -1,1 1,1 NS
Table 9: Gene expression levels for AMIOD as determined by qPCR in 5 mice.
Compound AMIOD AMIOD AMIOD AMIOD AMIOD MW AMIOD test
Gene *fold change 1 *fold change 2 *fold change 3 *fold change 4 *fold change 5
Bcl2111 -3,1 -2,1 -1,9 -2,1 -2,8 *
Parp 16 -1,2 -1,6 -1,2 -1,4 -1,8 *
Mras 1,1 1,0 1,1 1,1 -1,0 NS
Myo 1e -1,1 -1,3 -1,5 -1,1 -1,3 *
Nme6 1,3 -1,4 -1,1 -1,1 1,1 NS
ABCG5 1,2 -1,6 1,2 1,1 -1,3 NS
ABCG8 2,0 -1,6 1,1 1,1 -1,1 NS
SERPINE1 -1,7 -1,4 1,4 1,5 -3,5 NS
BAAT 1,8 -2,2 1,1 -1,0 -1,7 NS
KLF15 2,6 -1,8 -1,5 -1,4 -1,3 NS
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indicator of the cholestatic properties of a compound.
[0014] Hence, the invention relates to an in vitro method for determining whether a compound has cholestatic properties,
comprising the step of exposing a liver cell to the compound, incubating the liver cell with the compound for an appropriate
amount of time, determining the expression level of genes Bcl2l11, Parp 16, Mras, Myo1e, Nme6 ABCG5, ABCG8,
SERPINE1, BAAT, and KLF15 in the liver cell, wherein an aberrant expression of more than 4 of these genes indicates
that the compound has cholestatic properties.
[0015] More than 4 in this respect means at least 5, such as 5, 6 or 7 or more.
[0016] Any liver cell will be useful in a method according to the invention, however, precision cut liver slices are
preferred. Hence, the invention relates to a method as described above wherein the liver cell is comprised in a mouse
precision cut liver slice (PLCS).
[0017] The term "aberrant expression" as used herein is meant to indicate that the expression of a gene in a cell
exposed to the test compound is increased or decreased in comparison to the expression of the same gene in a cell
which is not exposed to the compound. The change in gene expression is usually expressed as fold change or a ratio.
A skilled person will appreciate the metes and bounds of these terms. Any method of determining whether a gene is
overexpressed or underexpressed will be useful in a method according to the invention, however, qPCR is preferred
because of its ease of use and potential to standardize. Moreover, qPCR test for this purpose are commercially available.
Therefore, the invention also relates to a method as described above wherein the step of determining the expression
level of genes Bcl2l11, Parp 16, Mras, Myo1e, Nme6 ABCG5, ABCG8, SERPINE1, BAAT, and KLF15 is performed by
quantitative PCR.
[0018] The skilled person will appreciate that any significant fold change may be used in a method according to the
invention. In a preferred embodiment, the cut off value for determining whether an expression is increased or decreased
is a fixed value, such as a fold change of at least 1,25 or -1,25, such as 1,5 or -1,5. Hence, the invention also relates to
a method as decribed above wherein the aberrant expression is an overexpression with a fold change of at least 1.25
or an underexpression with a fold change of at least -1.25.
Examples
Example 1: Preparation and culture of liver slices
[0019] 23-weeks old male C57BL/6 mice were obtained from Harlan (Horst, The Netherlands). Animals were kept for
1 week at a housing temperature of 22°C and at a relative humidity of 30-70%. The lighting cycle was 12-h light and 12-
h dark. At the age of 24 weeks animals were sacrificed by an overdose of isoflurane. The treatment protocol was approved
by the Ethical Committee for Animal Experiments at Wageningen University.
[0020] Immediately after the animals were killed the liver was perfused with PBS and placed in ice-cold Krebs-Henseleit
buffer (KHB) (pH 7.4, supplemented with 11 mM glucose). Liver tissue was transported to the laboratory within approx-
imately 30 min and cylindrical liver cores were produced using a surgical biopsy punch with diameter of 5 mm (KAI,
SynErgo Europe, Romania). Liver cores were placed in a Krumdieck tissue slicer (Alabama Research and Development,
Munford, AL) filled with ice-cold KHB aerated with carbogen and supplemented with 11 mM glucose. Precesion cut liver
slices (PCLS) with a diameter of 5 mm, a thickness of 0.2 mm and a weight of approximately 10 mg were prepared.
Immediately after preparation, slices were transferred into culture plates filled with pre-warmed (37 degrees C) Williams
E medium (WEM). Three liver slices were pre-cultured in one well of the 6-well plate filled with 4 ml of WEM for one
hour with continuous shaking (70 rpm). Incubations were performed in an oxygen controlled incubator (Galaxy 48 R
New Brunswick, Nijmegen, the Netherlands) at 80% of oxygen; 5% CO2 and the remaining gas volume was filled up to
95% with N2. After one hour of pre-incubation, media were removed and replaced with fresh media containing test
compounds or appropriate solvents. After incubations, samples were snap-frozen in liquid nitrogen and stored in -80 °C
for further analysis. Samples dedicated to histology were stored in 4 % formaldehyde at room temperature.
Example 2: Cytotoxicity analysis - dose selection experiments
[0021] PCLS were exposed to different model compounds inducing cholestasis, steatosis, necrosis, and to compounds
that are not hepatotoxic in vivo. These compounds were selected based on literature search. As pro-cholestatic model
compounds CyclosporinA (CsA) and chlorpromazine (CPZ) were selected. For steatosis tetracycline, valproic acid, and
amiodarone were selected. As pro-necrotic drugs acetaminophen, paraquat and isoniazid were used.
[0022] To select a non-toxic dose used for the exposure experiments, the following concentrations ranges were tested:
cyclosporinA 0-80 mM, chlorpromazine 0-80 mM, tetracycline 0-100 mM, valproic acid 0-500 mM, amiodarone 0-100 mM,
acetaminophen 0-3000 mM, paraquat 0-10 mM, and isoniazid 0-1000 mM. CyclosporinA, chlorpromazine, tetracycline,
amiodarone, acetaminophen, paraquat were dissolved in DMSO, valproic acid was dissolved in ethanol (EtOH), and
isoniazid were dissolved in PBS. The compounds were added to the culture medium at a final concentration of 0.1%
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vol/vol in an appropriate solvent (DMSO, EtOH, or PBS). Slices incubated with the solvents at 0.1 % vol/vol served as
controls. Toxicity was assessed with standard biochemical assays indicative for slices viability: LDH, ATP, and protein
assay. Dose selection experiments were performed in slices obtained from at least two mice.
Example 3: PCLS exposure experiments
[0023] PCLS were incubated at the same conditions as described above. Slices were exposed for 24 and 48 hours
to one concentration of the tested compounds or controls. Concentrations used in the exposure experiments were
preselected in the dose selection experiments for each drug individually. The highest concentration that did not cause
significant increase of toxicity assessed by biochemical assays (LDH, ATP, and protein assay) was selected. The
concentrations used in the exposure experiments were as follows; for the cholestatic exposures 40 mM CsA and 10 uM
CPZ. For the steatotic exposures: 40 mM tetracycline, 200 mM valproic acid, and 50 mM amiodarone. For the necrotic
compounds: 1000 uM acetaminophen, 5 mM paraquat and 1000 uM isoniazid. Liver slices obtained from five mice were
used in five toxic compound or control exposure experiments performed at the same time. Dose selection experiments
and exposure experiments were performed at different days. Therefore, ATP, LDH, and protein assays were performed
again for the exposure experiments to confirm that the selected doses did also not affect slice viability in these experiments.
Example 4: ATP and protein measurements
[0024] For each ATP and protein measurement a total of three co-cultured slices were placed in 400 mL Cell Lytic MT
buffer (Sigma, Zwijndrecht, the Netherlands). In order to compare ATP and protein content in liver slices from different
experiments, both ATP and protein were normalized on mass of liver slices. Therefore, the mass was registered for
each individual exposure and was for three slices 30 mg 6 25%. Slices were homogenized (6500 g, 8°C) two times for
15 sec using a tissue homogenizer (Precellys 24 Bertin Technologies, Labmakelaar Benelux B.V. Rotterdam, The
Netherlands). To remove cellular debris, the homogenates were centrifuged for 5 min (14000 g, 8°C) and the remaining
supernatant was divided into two portions of 200 mL. One portion was stored at -80°C for protein measurements and
the second 200 mL portion was mixed with 100 mL of ATP lytic buffer (ATPlite, Perkin Elmer, Oosterhout, The Netherlands)
for ATP measurements. ATP was measured according to the manufacturer’s description using a microplate reader
(Synergy TM HT Multi Detection Microplate Reader, Biotek Instruments Inc, Abcoude, the Netherlands) with settings
for luminescence: 590/635 nm, top measurement, and sensitivity 230. ATP determination was performed in technical
duplicates and luminescence values were recalculated into mM ATP in total liver slices extracts. ATP concentration was
normalized on mass of liver slices used for one ATP extraction. ATP levels in toxic compounds exposure experiments
are expresses as a relative value compared to control.
[0025] The protein concentration was determined according to the Bradford method (Protein assay, BioRad,
Veenendaal, The Netherlands). Protein samples of 2 mL were diluted 80 times in PBS and measured according to the
manufacturer’s instructions. BSA was used as a standard and each measurement was performed in duplicate. The
protein concentration was expressed as mg protein per mL of total protein extract. The protein content was normalized
on mass of liver slices used for protein extraction and was expressed as a relative protein content compared to protein
content measured in control.
Example 5: Lactate dehydrogenase (LDH) cytotoxicity assay
[0026] Lactate dehydrogenase activity in the culture medium of slices was performed according to the manufacturer’s
protocol (Cytotoxicity Detection Kit (LDH), Roche Diagnostics, Almere, the Netherlands). In brief, culture medium was
diluted 5 fold with PBS and mixed with 100 mL reaction mixture from the kit. After 15 minutes of incubation at room
temperature, samples were measured at 490 nm using a Synergy TM HT Multi Detection microplate reader. LDH leakage
is expressed as a relative value compared to control.
Example 6: Triglycerides (TG) measurements
[0027] Three liver slices cultured together were used to make a homogenate in 300 mL buffer containing 10mM Tris,
1mM EDTA (pH 7.4) and 250 mM sucrose. Aliquots of 10 mL of the liver slices homogenates were used in the assay
and measurements were performed according to the manufacturer’s protocol (triglycerides liquicolor mono, Instruchemie,
Delfzijl, the Netherlands). TG values were measured in mM of total extract and are expressed as a relative value compared
to control.
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Example 7: DNA microarray hybridizations
[0028] Gene expression analysis in liver slices incubated for 24 hours with the pro-cholestatic, steatotic, and necrotic
compounds as well as the controls was performed on the HT Mouse Genome 430 PM array plate(s) using the Affymetrix
GeneTitan system. RNA was extracted from three slices cultured together per one exposure experiment using the
RNeasy Tissue Mini Kit (Qiagen, Venlo, The Netherlands) according to the manufacturer’s instructions. RNA concen-
tration and purity were assessed spectrometrically using a Nano Drop ND-1000 spectrophotometer (Isogen IJsselstein,
The Netherlands) by measuring absorption ratios at 260/280 and 230/280 nm. The integrity of the RNA samples was
examined using the Shimadzu MultiNA Bioanalyzer (Tokyo, Japan). Biotin- labelled cRNA was generated from high-
quality total RNA with the Affymetrix 3’IVT Express Kit (Affymetrix, Santa Clara, CA, USA) according to the manufacturer’s
specifications with an input of 100 ng total RNA. The Agilent Bioanalyzer (Amstelveen, the Netherlands) and Shimadzu
MultiNA Bioanalyzer (Tokyo, Japan) were used to evaluate the quality of cRNA in order to confirm if the average fragment
size was according to Affymetrix’ specifications. Per sample, 7.5ug cRNA of the obtained biotinylated cRNA samples
was fragmented and hybridized in a final concentration of 0.0375 ug /ul on the Affymetrix HT Mouse genome 430 PM
array (Affymetrix, Santa Clara, CA, USA. After an automated process of washing and staining by the GeneTitan machine
(Affymetrix, Santa Clara, CA, USA) using the Affymetrix HWS kit for Gene Titan, absolute values of expression were
calculated from the scanned array using the Affymetrix Command Console v 3.2 software. The data Quality Control was
performed in the program Affymetix Expression Console v 1.1 software to determine if all parameters were within quality
specifications. The Probe Logarithmic Intensity Error Estimation (PLIER) algorithm method was used for probe summa-
risation (Qu et al. 2010).
[0029] In order to monitor the sample independent control and the performance of each individual sample during
hybridization, hybridizations controls were added to the hybridization mixture. The sample dependent controls such as
internal control genes, background values, and average signals were used to determine the biological variation between
samples. In conclusion, all the data were within data Quality Control thresholds, according to Affymetrix Expression
Console specifications. Non-normalized data in a form of the Cell Intensity File (*.CEL) were re-annotated (EntrezGene
htmg430pm_Mm_ENTREZG) and the data were RMA normalized (Jetten et al. 2012; Qu et al. 2010).
Example 8: Biomarkers verification
[0030] In order to identify biomarkers indicative for the development of cholestasis, three complementary approaches
were applied. In the first approach, DNA microarray data obtained from slices exposed to pro-cholestatic model com-
pounds (CsA and CPZ) were subjected to analysis of variance (ANOVA). Genes with p<0.05 were selected for Venn
diagram analysis and genes that were overlapping between the three treatments served as potential biomarkers.
[0031] In the second approach, the significant genes identified by GSEA, were used as input for Venn diagram. Similarly
to the first approach, genes overlapping between the three treatments were selected as potential biomarkers. Venn
analysis was performed using an open access tool http://bioinfogp.cnb.csic.es/tools/venny/index.html.
[0032] In the third approach, a random forest was applied. This method was conducted as described previously
(Bayjanov et al. 2012). Briefly, genes associating to samples of the two classes (CsA and CPZ) were determined by the
random forest based tool PhenoLink using default parameters (Bayjanov et al. 2012). Random forest was used to train
500 decision trees, where each tree is trained on different subsets of the samples and genes. Using the local importance
values, a total of 17278 non-informative genes (genes not contributing to distinguish the three classes) were removed.
After this step, 28 genes remained that were ranked based on the averaged local importances per class.
[0033] Furthermore, biomarkers’ expression values (derived from the DNA microarray data) were log2 transformed
and median centered followed by hierarchical clustering using default options in Genesis (http://genome.tugraz.at/gen-
esisserver/genesisserver_description.shtml). From this analysis, ten biomarkers were selected.
Example 9: Biomarkers validation by q-pcr
[0034] In further studies, expression of ten candidate biomarkers in PCLS was analyzed by q-pcr using the Biorad
CFX96 TM Real-Time Detection System (Bio-Rad, Veenendaal, The Netherlands) with the following cycling conditions:
15 min 95°C followed by 40 cycles of 15s 95 °C and 1 min 60 °C. Reactions were performed in 10 ml and contained 20
ng cDNA, 1x TaqMan PCR Master Mix (Applied Biosystems, Foster City, CA), and depending on the analysed gene,
250 nM probe and 900 nM primer (for actin b) or 1xTaqMan gene expression assay (for the remaining genes) (Applied
Biosystems, foster City, CA). Specific primer set for actinβ (ACTB) was developed with Primer Express 1.5 (Applied
Biosystems, Nieuwerkerk aan den IJssel, The Netherlands) and sequences were as follows, probe: TGT CCC TGT ATG
CCT CTG GTC GTA CCA C, forward primer: AGC CAT GTA CGT AGC CAT CCA, and reverse primer: TCT CCG GAG
TCC ATC ACA ATG (Szalowska et al. 2011). Primers for Kruppel-like factor 15 (KLF15), bile acid-CoenzymeA:amino
acid N-acyltransferase (BAAT), serine(or cysteine) peptidase inhibitor clade E, member 1 (SERPINE1/PAI1), ATP-
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binding cassette, sub-family G (WHITE), member 8 (ABCG8), ATP-binding cassette, sub-family G (WHITE), member 5
(ABCG5), non-metastatic cells 6, protein expressed in (nucleoside-diphosphate kinase) (Nme), poly (ADP-ri-
bose)polymerase family, member 16 (Parp16), muscle and microspikes RAS (Mras), myosinIE (Myo1e), and BCL2-like
11 (Bcl2l11) were purchased from Applied Biosystems.
[0035] The numbers of assays from Applied Biosystems are given in Table 10.
[0036] Data were analyzed with SDS 2.0 software (Bio-Rad). For each sample, the RT-PCR reaction was performed
in triplicate and the averages of the obtained threshold cycle values (CT) were processed for further calculations. To
check for contaminating DNA, samples without reverse transcriptase (-RT reaction) were analysed as well. For normal-
ization ACTB was used. Relative expression was calculated with Δ (Δ (CT))-method (Livak and Schmittgen 2001).
Example 10: Statistical analysis
[0037] Mann-Whitney test was used to calculate differences between controls and slices incubated with the tested
compounds for ATP, protein, LDH, TG, and bile acids. The cut off for statistical significance was set at a p-value < 0.05.
[0038] Mann-Whitney - test was used to determine if there was a significant difference in gene expression assessed
by q-pcr in slices exposed to different compounds. A p-value <0.05 was considered significant.
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Claims
1. In vitro method for determining whether a compound has cholestatic properties, comprising the step of exposing a
liver cell to the compound, incubating the liver cell with the compound for an appropriate amount of time, determining
the expression level of genes Bcl2l11, Parp 16, Mras, Myo1e, Nme6 ABCGS, ABCG8, SERPINE1, BAAT, and
KLF15 in the liver cell, wherein an aberrant expression of more than 4 of these genes indicates that the compound
has cholestatic properties.
2. In vitro method according to claim 1 wherein the liver cell is comprised in a mouse precision cut liver slice (PLCS).
3. Method according to claims 1 or 2 wherein the step of determining the expression level of genes Bcl2l11, Parp 16,
Mras, Myo1e, Nme6 ABCG5, ABCG8, SERPINE1, BAAT, and KLF15 is performed by quantitative PCR.
4. Method according to any one of claims 1 - 3 wherein the aberrant expression is an overexpression with a ratio of
at least 1.25 or an underexpression with a ratio of at least 0,75.
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